ERBB2 and breast carcinoma: The protein, after binding to a ligand, is activated by means of homo- or heterodimerization, leading to a cascade of events that activate its tyrosine kinase domain and promoting the rapid cell growth, differentiation, survival and migration associated with HER-2 positive breast cancer [5].